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Background and Objective: Type 2 diabetes (T2D) is rapidly increasing in incidence and has 
significant social and economic costs. Given the increasing cost of complications, even relatively short 
delays in the onset of T2D can significantly reduce long-term complications and costs. Equally, recent 
studies have shown the onset of T2D can be delayed by use of long-acting insulin, despite the risk and 
concomitant low adherence. Thus, there is a strong potential motivation to develop models of long-
acting insulin analogues to enable safe, effective use in model-based dosing systems. In particular, 
there are no current models of long-acting insulin Detemir and its unique action for model-based control. 
The objective of this work is to develop a first model of insulin Detemir and its unique action, and validate 
it against existing data in the literature. 
 
Methods: This study develops a detailed compartment model for insulin Detemir. Model specific 
parameters are identified using data from a range of published clinical studies on the pharmacokinetic 
of insulin Detemir. Model validity and robustness are assessed by identifying the model for each study 
and using average identified parameters over several dose sizes and study cohorts. Comparisons to 
peak concentration, time of peak concentration and overall error versus measured plasma 
concentrations are used to assess model accuracy and validity. 
 
Results: Almost all studies and cohorts fit literature data to within one standard deviation of error, even 
when using averaged identified model parameters. However, there appears to be a noticeable dose 
dependent dynamic not included in this first model, nor reported in the literature studies.  
 
Conclusions: A first model of insulin Detemir including its unique albumin binding kinetics is dervied 
and provisionally validated against clinical pharmacokinetic data. The pharmacokinetic curves are 
suitable for model-based control and general enough for use. While there are limitations in the studies 
used for validation that prevent a more complete understanding, the results provide an effective first 
model and justify the design and implementation of further, more precise human trials. 
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Type 2 Diabetes (T2D) is characterised by insulin resistance followed by reduced and eventually non-
existent endogenous insulin production, all of which lead to increasing and persistent hyperglycemia. 
Worldwide 400 million people live with T2D and it is estimated almost 200 million more people have 
undiagnosed diabetes, with significant increases of 30-50% predicted by 2030 [1-4]. Early detection 
and treatment reduces morbidity and mortality, improves quality of life, and thus reduces the social and 
economic healthcare burden [5]. 
 
Normal endogenous insulin secretion is bi-phasic, with a first phase impulse response to a meal added 
to a relatively constant basal secretion rate. Insulin analogues have been developed to replicate these 
two behaviours, with fast acting analogues used to replicate the impulse response, and slow acting 
analogues used to replicate basal secretion. Insulin Detemir™ (Nov Nordisk, Denmark) is one such 
slow acting basal insulin analogue [6]. However, while insulin therapy is commonly used in individuals 
with very high insulin resistance and/or failed insulin secretion, it is a last resort therapy in T2D for safety 
reasons [7-9].  
 
Insulin Detemir is subcutaneously injected as a hexameric unit, which then dissociates into monomers 
and dimers in the subcutaneous interstitium [10]. Insulin Detemir differs from endogenous human insulin 
in that a C14 fatty acid chain has been attached to the amino acid B29, and the amino acid threonine 
at B30 is omitted [11],  which, different to other long acting analogues, allows it to bind to albumin in 
both interstitial fluid and blood plasma. This binding means only 2 – 4% [10,12] of insulin Detemir is 
available for receptor binding to mediate glucose uptake at any time.  Its action is further prolonged due 
to strong self-association in the hexameric form [10].  
 
However, despite the rise of computer and model based glycemic control using insulin pumps [13-15], 
there are no current models of insulin Detemir and its unique action for use in model-based control 
methods for those type 1 and type 2 diabetic individuals using injected insulin (e.g. [16]). In particular, 
prior models of long acting insulin analogues do not include this albumin binding aspect [17-19], which 
makes the model unique in its own right.  
 
Equally, a validated model can be used to guide insulin dosing in model-based protocols for those using 
multiple daily injection to control glucose levels. A better understanding of the appearance profile would 
enable safe, more accurate control versus using current models for other analogues. In particular, while 
the model parameters can be modified in other insulin analogue models to provide an estimated 
appearance profile, it is not necessarily accurate, and they cannot model or account for both bound and 
unbound Detemir masses, all of which can lead to error and increased risk. 
 
This study aims to create a physiologically relevant pharmacokinetic model for the appearance of insulin 
Detemir in plasma and interstitium from an injection depot site. Data from pharmacokinetic studies in 
the literature are used for initial model validation, including a type 1 diabetic cohort and a type 2 diabetic 
cohort, where data on these specialised cohorts is often lacking. This pharmacokinetic model could 
prove useful in model-based glycemic control using multiple daily injection in lieu of insulin pumps to 
treat diabetes. More immediately, a validated model would also justify clinical studies on specific type 
1 and type 2 diabetes cohorts to optimise model parameters, as well as understand the variability of 
appearance, which is not possible with current data sets in the literature.
2.0 Methods: 
2.1 Model: 
A pharmacokinetic model of insulin Detemir in the subcutaneous (SC) fluid and plasma serum is 
presented pictorially in Figure 1. It contains all relevant compartments and bound/unbound states. In 
the local injection depot, three compartments describe hexameric Detemir ( 𝐼𝐷𝐻 , 𝑚𝑈), and both unbound 
(𝑄𝐷𝐹,𝐿𝑜𝑐𝑎𝑙 , 𝑚𝑈) and bound (𝑄𝐷𝐵,𝑙𝑜𝑐𝑎𝑙 , 𝑚𝑈) monomer/dimer Detemir in the local depot. Table 1 defines 


































Figure 1: Schematic of compartment model for the pharmacokinetics of Insulin Detemir 
Table 1: Summary and definition of parameters used in the model 
Parameter Value Units Source Definition 
𝐼𝐵𝑜𝑙𝑢𝑠 0.15-0.75 mU۰kg
-1 [20-22] Subcutaneous insulin Detemir injected 
𝑘𝑎 0.0078 min
-1 [23] Rate constant for the hexameric dissociation 
to dimers/monomers 
𝑘𝑏  min
-1 identified Rate constant for the diffusion of the unbound 
insulin from the local interstitium into the blood 
plasma 
𝑘1 0.96 min
-1 [10,12] Rate constant defining the binding of the 
insulin to albumin 
𝑘2 0.04 min
-1 [10,12] Rate constant defining the unbinding of the 
insulin to albumin 
𝑘𝑑𝑖  min
-1 identified Degradation rate constant of unbound insulin 
in the local depot 
𝑉𝐼 4.0 L [24] Plasma distribution volume 
𝑛𝐷𝐿  min
-1 identified Hepatic and renal insulin clearance rates 
𝑛𝐷𝐼 0.06 min
-1 [24] Trans-endothelial diffusion rate between the 
blood plasma and the interstitial fluid 
𝑛𝐷𝐶 0.032 min
-1 [24] Rate of degradation of the Detemir in the 
interstitial fluid 
These compartments are defined: 
?̇?𝑫𝑯 = −𝒌𝒂𝑰𝑫𝑯 + 𝑰𝑩𝒐𝒍𝒖𝒔𝜹(𝒕) (1) 
?̇?𝑫𝑭,𝑳𝒐𝒄𝒂𝒍 = 𝒌𝒂𝑰𝑫𝑯 − (𝒌𝒃 + 𝒌𝒅𝒊)𝑸𝑫𝑭,𝒍𝒐𝒄𝒂𝒍  − (𝒌𝟏𝑸𝑫𝑭,𝒍𝒐𝒄𝒂𝒍 −  𝒌𝟐,𝑰𝑭𝑸𝑫𝑩,𝒍𝒐𝒄𝒂𝒍) (2) 
?̇?𝑫𝑩,𝑳𝒐𝒄𝒂𝒍 = 𝒌𝟏𝑸𝑫𝑭,𝒍𝒐𝒄𝒂𝒍 −  𝒌𝟐𝑸𝑫𝑩,𝒍𝒐𝒄𝒂𝒍 (3) 
 
Where 𝐼𝐵𝑜𝑙𝑢𝑠 is the amount of subcutaneously injected insulin Detemir, 𝛿 is the Dirac delta function, 𝑘𝑎 
is the rate constant for the hexameric dissociation to dimers/monomers, 𝑘𝑏 is the rate constant for the 
diffusion of the unbound insulin from the local interstitium into the blood plasma, 𝑘𝑑𝑖 is the degradation 
of the unbound insulin in the local depot, 𝑘1 is the rate constant defining the binding of the insulin to 
albumin, and 𝑘2 is the rate constant defining the unbinding of the insulin to albumin. As evidence 
suggests dimers and monomers diffuse between plasma and interstitium at similar rates [25], and both 
dimers and monomers of this insulin analogue bind to albumin, these masses are combined. 
 
Insulin Detemir diffuses from the local depot into blood plasma, where it circulates and is free to 
equilibrate with the whole-body interstitial fluid compartment. Specifically, in Figure 1, 𝐼𝐷𝐹  (𝑚𝑈/𝐿) is the 
‘free’ unbound insulin Detemir in the blood plasma, 𝐼𝐷𝐵  (𝑚𝑈/𝐿)  is the bound insulin Detemir in the 
plasma, 𝑄𝐷𝐹 (𝑚𝑈/𝐿)  is the unbound insulin Detemir in the interstitial fluid and 𝑄𝐷𝐵 (𝑚𝑈/𝐿)  is the bound 





𝑄𝐷𝐹,𝑙 − (𝑛𝐷𝐿)𝐼𝐷𝐹 − 𝑛𝐷𝐼(𝐼𝐷𝐹 − 𝑄𝐷𝐹) − (𝑘1𝐼𝐷𝐹 − 𝑘2𝐼𝐷𝐵) (4) 
𝐼?̇?𝐵 = 𝑘1𝐼𝐷𝐹 − 𝑘2𝐼𝐷𝐵 (5) 
?̇?𝐷𝐹 = −𝑛𝐷𝐶𝑄𝐷𝐹 + 𝑛𝐷𝐼(𝐼𝐷𝐹 − 𝑄𝐷𝐹) − (𝑘1𝑄𝐷𝐹 − 𝑘2𝑄𝐷𝐵) (6) 
?̇?𝐷𝐵 = 𝑘1𝑄𝐷𝐹 − 𝑘2𝑄𝐷𝐵 (7) 
 
Where, in Equations (4)-(7) and in Table 1, 𝑉𝐼 is the volume of distribution (𝐿) of the insulin Detemir, 
which is assumed similar to that of human insulin. The parameter 𝑛𝐷𝐿 determines the hepatic and renal 
insulin clearances, 𝑛𝐷𝐼 the trans-endothelial diffusion rate between the blood plasma and the interstitial 
fluid, 𝑘1 the rate of binding of Detemir to albumin, 𝑘2 the rate of unbinding of Detemir from albumin, and 
𝑛𝐷𝐶 the rate of degradation of the Detemir in the interstitial fluid. Constants 𝑘1 and 𝑘2 govern binding 
and unbinding to albumin, and are assumed constant across the depot, plasma, and interstitial fluid, 
and are valued so at steady state 96% of insulin is bound to plasma albumin per literature reports 
[10,12,26-28]. Binding is a non-saturated process as albumin is plentiful relative to Detemir dose [10]. 
 
Values in Table 1 are defined from other models of human insulin pharmacokinetics in the literature for 
common kinetics. The parameter values identified from data in this study are specific to Detemir, and 
include 𝑘𝑏 , 𝑘𝑑𝑖 , and 𝑛𝐷𝐿, which are not previously reported elsewhere and are thus assumed to describe 
the dynamics most specific to insulin Detemir. These identified parameters were also selected based 
on model identifiability [29], and for their sensitivity in controlling the model dynamics in terms of peak 
concentration and clearance rates of insulin Detemir, as measured in plasma clinically. In particular, the 
clearance 𝑛𝐷𝐶 is known to trade off with 𝑛𝐷𝐿 , so 𝑛𝐷𝐶 is set to a human insulin value, and only 𝑛𝐷𝐿 is 
uniquely identified. The input value of the bolus, 𝐼𝐵𝑜𝑙𝑢𝑠 , is the experimental input controlled and recorded 
in each study. 
 
2.2 Data: 
A literature search of PubMed and Google was carried out to find experimental studies of insulin Detemir 
pharmacokinetics, using combinations of the search terms ‘Detemir”, “Insulin”, “NN304” and 
“pharmacokinetics”. Five studies were found [20-22,30,31] which measured and reported serum insulin 
Detemir, where serum is defined as the total amount of bound and unbound insulin Detemir in blood 
plasma. The studies used a wide range of doses from 0.15 - 0.75 U/kg, with equally varied cohorts and 
protocols, and are summarised in Table 2.  
 
Briefly, the study by Jhee et al compared Detemir pharmacodynamics in American Caucasians and 
Americans of Japanese heritage [22]. Brunner et al examined the pharmacokinetics of Detemir at 
different doses, and compared this to NPH insulin [20]. Heinemann et al  examined the time action 
profile of insulin Detemir at three different doses [30], while Danne et al examined differences in the 
pharmacokinetic profiles between adults and adolescents with T1D [21]. Morrow et al examined the 
additive effect of Detemir and liraglutide in subjects with T2D [31]. Where units differed between studies 
and models, the conversion factor of 1 μU/L = 6.0 pmol/L was used for plasma insulin [32]. There is 
thus a range of doses, subjects (N = 100 total), and clinical contexts, enabling identification of a general 
model across all of them that is not specific to a particular cohort or context. 
 
Table 2: Studies reporting PK profiles and data for insulin Detemir. All values are mean ± SD where 



































0.19 1.82±0.5ˣ 5.38±2.01 0.99±0.15ˣˣ 
0.38 4.14±1.16ˣ 6.0±2.28 2.39±0.36ˣˣ 
0.75  6.88±1.93ˣ 6.23±2.10 4.65±0.70ˣˣ 

















0.19 1.74±0.49ˣ 4.53±1.97 0.97±0.15ˣˣ 
0.38 3.18±0.89ˣ 6.03±2.62 2.11±0.32ˣˣ 
0.75  5.80±1.60ˣ 6.93±2.40 4.29±0.64ˣˣ 
Brunner et al. 2000 
[20] – Healthy 
males 




0.3 1.18±0.39 3.6±1.17 0.49±0.10 
0.6 1.81±0.48 4.5±2.07 0.93±0.14 
Heinemann et al. 

















0.15 0.61±0.14 4.45±1.4 0.34±0.04 
0.3 1.05±0.28 5.42±1.6 0.67±0.08 
0.6 2.03±0.46 5.37±1.2 1.23±0.21 
Danne et al. 2003 
[21] – T1D adults 
11 22.8±6.4 23.4±1.9 76.5±6.7 Thigh SC 0.5 4.64±2.30 8.05±3.43 3.38±1.42 
Morrow et al. 2011 
[31] – T2D adults 




0.5 3.73±1.84* 9.5±4.1** 3.11±1.3*** 
 
 
Reported values of peak concentration and its time of occurrence (Cmax, tmax), as well as the AUC of 
measured serum insulin Detemir are also summarised in Table 2, and will be compared to identified 
model values. Where estimations of variance were missing, standard deviations (SDs) have been 
computed based on SD’s as a % of the mean value from the study (i.e. Standard Error), or studies most 
similar to the current study. This latter approximation was made for data from Jhee et al and Morrow et 
al in the absence of any better data to assess variability, where such an assumption assumes only that 
insulin assays and sampling procedures have similar variability across studies, which is not 
unreasonable. 
 
2.3 Model Identification: 
Values for 𝑘𝑑𝑖, 𝑘𝑏, and 𝑛𝐷𝐿 are identified using data from the studies in Table 2 using a Gauss Newton 
parameter identification algorithm. The numerical Jacobian was calculated using a parameter 
ˣ SD not given in paper so value of 28% is used based on Brunner and Heinemann values 
ˣˣ SD not given in paper so value of 15% is used based on Brunner and Heinemann values 
* SD not given in paper so value of 49% is used based on Danne value 
** SD not given in paper so value of 43% is used based on Danne value 
*** SD not given in paper so value of 42% is used based on Danne value 
perturbation of ± 1% of the parameter value. To stabilise convergence, the new parameter estimate 
was defined as 10% of the new Gauss Newton estimate added to 90% of the previous parameter values, 
limiting step size for convergence. Model errors were plotted to ensure convergence to steady state 
was obtained, where convergence was measured as a change in least squares error less than 1.0e-4 
between iterations. Least squares errors were calculated as the difference between literature reported 
serum Detemir insulin and the modelled sum of plasma free and bound Detemir insulin (𝐼𝐷𝐹 +  𝐼𝐷𝐵) to 
match the published reports.  
 
The model is theoretically and practically identifiable [33]. However, there is also some trade off of the 
dynamic effect each variable has on the final model solution, even if the identified solution is optimal for 
the data used in the identification process. Specifically, the value of  𝑘𝑑𝑖 mainly affects Cmax , while 𝑘𝑏 
affects primarily tmax, and 𝑛𝐷𝐿 primarily affects the clearance/disappearance decay slope, but in all cases 
it is the net overall effect that yields the final curve. The identification approach provides a global 
optimum, and the generalisability of the results to reported experimental data will assess whether the 
identified values are robust. 
 
2.4 Comparison to literature reported PK outcomes: 
Area under the curve (AUC), maximum serum concentration (Cmax) and time of maximum concentration 
(tmax) for the identified model results are compared to those from the published studies in Table 2. After 
values are identified for each individual data set and compared to the reported PK values for that data 
set in Table 2, the mean identified parameter values across an entire study are used to assess model 
robustness in a further comparison to the reported data, as well as assessing the robustness of the 
model dynamics and parameters as identified. Finally, the identified parameters for the two best 
performing data sets are averaged and simulated to assess inter-study robustness and variability of the 
model. 
 
The identified model was assessed as accurate and robust if the model using identified average 
parameter values was within 1 standard deviation of the measured data set value, thus accounting for 
measurement error with a very conservative metric.  
 
3.0 Results: 
3.1 Identification and Identified Model Fit: 
Model parameter values identified from literature data for each data set across all studies are shown in 
Table 3 and corresponding model fits in Figure 2. The model did not converge for the data from the 
Morrow et al studies [31], potentially due to the very specific diabetes cohort used yielding very different 
curves from the model dynamics, or equally due to measurement or other study errors. The results for 
Morrow et al are thus not presented. The data from Brunner et al and Heinemann et al had considerably 
lower serum insulin Detemir concentrations than Jhee et al at higher initial bolus amounts, showing 
significant variability in the reports, as well, which yield different pharmacokinetic parameter values.  
 









Jhee et al. 2004 [22] 
Caucasian cohort 
0.19 0.0530 0.0155 0.3344 
0.38 0.0720 0.0191 0.2746 
0.75 0.0754 0.0080 0.1071 
Jhee et al. 2004 [22] 
Japanese cohort 
0.19 0.0378 0.0388 0.6270 
0.38 0.0456 0.0163 0.2767 
0.75 0.0730 0.0106 0.1069 
Brunner et al. 2000 [20] 0.3 0.0605 0.0506 2.1227 
0.6 0.0635 0.0258 1.4148 
Heinemann et al. 1999 [30] 0.15 0.0705 0.0194 0.7222 
0.3 0.0803 0.0085 0.3195 
0.6 0.0920 0.0082 0.2884 
Danne et al. 2003[21] 0.5 0.0444 0.0072 0.1344 




Averaged parameter values across each study are shown in Table 4. PK parameters for human insulin 
from Lotz et al [24], Wong [23] and Shimoda et al [34], are presented for comparison. The value of 𝑛𝐷𝐿 
is close to the human insulin literature value in general and especially for the Jhee et al and the 
Heinemann et al cohorts.  The Brunner et al averaged value of 𝑛𝐷𝐿is not physiologically realistic as it is 
extremely high [24]. The other results and comparisons show broadly similar values although the 
identified value for kb for Danne et al is significantly lower than the others and the added comparator 
studies. Overall, there is variability both between studies and within studies, potentially reflective of 





Table 4: The averaged parameters from the values found in Table 3 where the latter three results are 
shown for comparison to common values identified in prior studies for added comparison. The Jhee et 








3.2 Comparison to literature reported PK outcomes for identified models for each data set: 
To evaluate the model fit for each individual identified data set PK parameters AUC, Cmax and tmax are 
compared in Table 5, where a tick () indicates the model results within 1 SD criteria is met. In all cases, 
the individually identified models were able to match reported literature kinetics within 1 SD, indicating 
the model was able to capture all key pharmacokinetics of insulin Detemir for each data set and study, 
individually. The corresponding identified model fits are shown in Figure 2.  
 
Table 5: Comparison of the model to literature reported PK outcomes for the individually identified data 
sets. A tick () indicates criteria of within 1 SD is met, a cross (X) is unmet. 
Paper Dose 
Size 
AUC (pmol۰min/L۰106)  Cmax (pmol/L x103)  tmax (hours) 
 ( U/kg) Model Data± SD  Model Data± SD  Model Data ± SD  
Jhee et al. 2004 [22] 
Caucasian cohort 
0.19  1.06  0.99±0.15  1.38 1.82±0.5  4.98 5.38±2.01  
0.38  2.40 2.39±0.36  3.46 4.14±1.16  4.95 6.0±2.28  
0.75  4.87 4.65±0.70  5.49 6.88±1.93  6.95 6.23±2.10  
Jhee et al. 2004 [22] 
Japanese cohort 
0.19  0.99 0.97±0.15  1.47 1.74±0.49  4.46 4.53±1.97  
0.38  2.21 2.11±0.32  2.66 3.18±0.89  5.58 6.03±2.62  
0.75  4.87 4.29±0.64  5.49 5.80±1.60  6.95 6.93±2.40  
Brunner et al. 2000 [20] 0.3  0.49 0.49±0.10  0.93 1.18±0.39  3.02 3.6±1.17  
0.6  0.95 0.93±0.14  1.52 1.81±0.48  3.96 4.5±2.07  
Heinemann et al. 1999 [30] 0.15  0.33 0.34±0.04  0.55 0.61±0.14  3.98 4.45±1.4  
0.3  0.63 0.67±0.08  0.94 1.05±0.28  5.01 5.42±1.6  
0.6  1.19 1.23±0.21  1.85 2.03±0.46  5.03 5.37±1.2  
Danne et al. 2003 [21] 0.5 3.28 4.64±2.30  3.54 3.38±1.42  7.10 8.05±3.43  
 
Paper 𝒌𝒅𝒊 𝒌𝒃 𝒏𝑫𝑳 
Jhee et al. 2004 [22] – both cohorts 0.0594 0.0181 0.288 
Brunner et al. 2000 [20] 0.0620 0.0382 1.769 
Heinemann et al. 1999 [30] 0.0809 0.012 0.440 
Danne et al. 2003 [21] 0.0444 0.0072 0.134 
Shimoda et al. 1997 [34] 0.0029  - - 
Wong et al. 2008 [35] - 0.0649 - 
Lotz et al. 2008 [24] - - 0.22* 
*Value is the sum of the hepatic and renal clearances in Lotz et al. 
 
Figure 2: Model fits to different dose sizes in individual data sets for a) Jhee et al’s Caucasian cohort 
[22], B) Jhee et al’s Japanese cohort [22], c) Brunner et al [20], d) Heinemann et al [30], e) Danne et 
al [21]. Serum insulin Detemir as plotted represents the total of bound and unbound plasma Detemir 
(IDF + IDB).  
 
 
3.2 Comparison to literature reported PK outcomes using averaged identified model values: 
The comparison of averaged parameter values from Table 4 for those data sets is shown in Figure 3 
and Table 6. Due to the very large outlier values in the single data set for Brunner et al in Table 3, the 
averaged values for Heinemann et al were used as they have similar dose sizes.  
 
Results for tmax matched the literature reported values for all data sets, and other PK outcomes matched 
for most data sets. However, it tended to overestimate tmax for lower bolus sizes and underestimate it 
for higher bolus sizes. This latter result suggests some model kinetics may be dependent on bolus size.  
 
Equally, the Jhee et al Caucasian cohort, the model underestimated AUC by more than 1 SD for the 
lowest Detemir bolus dose. Both of the models in the Brunner et al set underestimated AUC and were 
outside of 1 SD of literature values. This latter results is probably due to the Heinemann et al parameter 
values used for this simulation, but equally showing reasonable robustness across studies.  
 
Overall, there is a small degree of dose specific response to insulin Detemir, which is not captured by 
averaged values across a study. This inter-study variability is reflected in Table 4. Equally, those results 
outside the conservative 1 SD criterion were within 2 SDs, which is also evident in the qualitatively good 
fits in Figure 3. Hence, the large number of ticks in Table 6 (32 of 36 possible comparisons, 88%) 
indicates the average parameters for each study perform well, and their broad similarity indicates 
reasonable robustness overall. 
 
 
Table 6: Validation of the model for the averaged parameters in Table 4. A tick () indicates criteria of 
within 1 SD is met, a cross (X) is unmet.  
Paper Dose 
Size 
AUC(pmol۰hours/L۰106)  Cmax (pmol/L x103) (0.28) tmax (hours) 
 ( U/kg) Model Data  Model Data  Model Data ±SD  
Jhee et al. 2004 [22] 
Caucasian cohort 
0.19 1.26  0.99±0.17 X 1.70 1.82±0.5  4.98 5.38±2.01  
0.38 2.51 2.39±0.36  3.39 4.14±1.16  4.95 6.0±2.28  
0.75 5.02 4.65±0.70  6.78 6.88±1.93  4.98 6.23±2.10  
Jhee et al. 2004 [22] 
Japanese cohort 
0.19 0.96 0.97±0.15  1.3 1.74±0.49  5.45 4.53±1.97  
0.38 1.91 2.11±0.32  2.59 3.18±0.89  5.01 6.03±2.62  
0.75 3.80 4.29±0.64  5.13 5.80±1.60  4.98 6.93±2.40  
Brunner et al. 2000 [20] 0.3 0.72 0.49±0.10 X 1.15 1.18±0.39  4.50 3.6±1.17  
0.6 1.43 0.93±0.14 X 2.30 1.81±0.48 X 4.55 4.5±2.07  
Heinemann et al. 1999 [30] 0.15 0.36 0.34±0.04  0.57 0.61±0.14  3.98 4.45±1.4  
0.3 0.71 0.67±0.08  1.14 1.05±0.28  4.00 5.42±1.6  
0.6 1.43 1.23±0.21  2.29 2.03±0.46  4.05 5.37±1.2  






Figure 3: Model fits to different dose sizes for averaged parameters for data from a) Jhee et al’s 
Caucasian cohort [22], B) Jhee et al’s Japanese cohort [22], c) Brunner et al [20], d) Heinemann et 
al [30], e) Danne et al [21]. Serum Detemir represents the total of bound and unbound plasma 
Detemir (IDF + IDB). 
 
 
Finally, to assess average kinetic parameters, kinetic parameter values were averaged across the 
Heinemann et al and Jhee et al data sets and the model fits are shown in Figure 4. The inter study 
variability leads to the model fit underestimating the Jhee et al data and overestimating the Heinemann 
et al data. Again, these results indicate dose specific and/or cohort specific dynamics not fully capture 
although qualitative fits are acceptable. 
 
 
Figure 4: Model fits to different dose sizes for averaged parameters across both the Jhee and Heinemann studies for 
data from a) Jhee et al’s Caucasian cohort [22], B) Jhee et al’s Japanese cohort [22], and c) Heinemann et al [30]. 





A model was fit to reported literature pharmacokinetics of insulin Detemir, and was able to achieve good 
model fits and match most reported literature pharmacokinetics to within the experimentally reported 1 
SD for both healthy, and T2D patients. The model is thus able to capture all major kinetics, and can be 
used to model the appearance of subcutaneously administered insulin Detemir. The rate constant from 
the local interstitium to the blood plasma, 𝑘𝑏, was consistently much lower than the value for human 
insulin [23]. This outcome suggests there is an extra prolonging mechanism not in the model or the FFA 
chain slows trans-capillary diffusion requiring a different assumption and a new parameter fit.  
 
Insulin Detemir is able to bind to albumin in its hexameric form [10], which was not included in the 
pharmacokinetic model as the percentage binding in hexameric form is likely much lower [10]. This 
dynamic may explain the lower rate of 𝑘𝑏, as it would slow down the insulin absorption into the blood 
plasma. Additionally, 𝑘𝑏 in Wong is modelled using a much lower value for 𝑉𝐼, the volume of distribution, 
which would affect 𝑘𝑏. Overall,  𝑘𝑏 is relatively consistent across all studies in this analysis and together 
 𝑘𝑎 and  𝑘𝑏 seem to acceptably control the overall appearance of Detemir insulin into plasma, where it is 
this overall appearance that is important to the model. 
 
The degradation rate of insulin in the local interstitium, 𝑘𝑑𝑖, was much higher than suggested by the 
literature [23]. This result suggests insulin Detemir is preferentially cleared from this space, or there is 
another loss of insulin Detemir not accounted for in the model or reported in the literature we have seen. 
However Wong et al’s study included 𝑘𝑑𝑖 acting on multiple compartments in the subcutaneous model, 
where here it only acts on free monomeric/dimeric Detemir at the depot. It was also derived using a 
lower 𝑉𝐼 value than in Wong et al based on newer information. Equally, the fraction of bound insulin 
Detemir could be different to the value of 96% considered in this study, where there are reports as high 
as 98-99%, although literature suggests bound rates are similar between interstitial fluid and blood 
plasma [10,12,26-28].  
 
The identified hepatic/renal clearance constant, 𝑛𝐷𝐿 , is very similar in value to the literature [24]. The 
exception is the data from Brunner et al, where peak insulin Detemir concentrations were much lower 
at similar dose sizes in comparison to other studies, suggesting an added un-modelled loss. Overall, 
the loss in Brunner et al is extremely high, as well, and may reflect the particular study cohort, 
methodology, or assay conditions. The overall comparable 𝑛𝐷𝐿 value suggests unbound insulin is able 
to be cleared through the liver at a similar rate to human insulin.  
 
One limitation is the literature reported values for Cmax often differed from the corresponding graphed 
study results by 13.5±7.6% (mean±SD). This difference may lead to inaccuracy in the comparison 
method since the kinetic parameters are determined by fitting to the graphical data and the model fits 
are compared to the reported values from the original papers. It is unclear why this contradiction exists 
within the original literature studies. If this extra source of variation is included, then model derived 
values for Cmax are within the acceptable range for all data sets, and for the average study identified 
parameter values, which significantly improves the reported results.  
 
As literature suggests the fraction of bound Detemir insulin is approximately similar in the blood plasma 
and interstitial fluid, this fraction (affecting 𝑘1 and 𝑘2) was held constant in all compartments. This 
percentage bound is approximately 96-98% at steady state [10,12]. The value of 96% was used as it 
improved model convergence, while maintaining biologically relevant numbers and results. The model 
could be identified for higher values of the binding constant and would give almost identical 
concentrations in the blood plasma accompanied by an increase in the fitted kinetic parameters.  
 
Dea et al [12] compared human insulin to insulin Detemir in dogs to determine if the rate constants for 
the Detemir clearance were reduced based on the binding affinity to albumin. Dea et al found that 96.4% 
of Detemir would be albumin bound in interstitial fluid, and 98.3% in blood plasma. However, due to the 
simplicity of their two compartmental model, and minimal amount of data, the difference between the 
two binding values is likely to be clinically insignificant and statistically insignificant in the study report. 
There is also no proposed physiological explanation as to why binding percentages would be different 
in the plasma and interstitial fluid. Dea et al also noted the transport of insulin Detemir from the blood 
plasma to interstitium was higher than expected based on their binding predictions, suggesting there 
was more unbound insulin Detemir than predicted, which would justify a lower value. Thus, the 96% 
bound value used here is justified based on limited literature data available and the inability to assess 
a better value without further extended tests. 
 
The study by Danne et al involved a cohort of Type I diabetic patients, compared to the other studies 
that used healthy cohorts (Table 2). The parameter values 𝑘𝑏 and 𝑛𝐷𝐿 were both lower for the Danne et 
al cohort (𝑘𝑏 = 0.044, 𝑛𝐷𝐿 = 0.134) than the values for the healthy cohorts ( 𝑘𝑏 = 0.0594 to 0.0809, and 
𝑛𝐷𝐿 = 0.288 to 0.440).  This difference could potentially be caused by diabetic patients being much more 
insulin resistant, so insulin is used more slowly and remains in blood longer, leading to higher Tmax and 
Cmax [36].  There is also the potential for kidney failure to some level in this cohort [37], so 𝑛𝐾would be 
lower and would cause a higher Cmax. In the first case, a separate model would be required for type 1 
diabetes patients, and in the second a different value for kidney clearance would have to be used in 
identifying the model parameters, which was not the case here. 
 
There was a large variation in serum concentrations for the different studies even at similar bolus 
amounts and especially for the Jhee et al study compared to the Heinemann et al  and Brunner et al 
studies. The most probable reason for this variability is differences in the methods used. The basic 
design of the three studies was similar in the fact patients were fasted beforehand, only received 
intravenous infusions of glucose during the test, and received a subcutaneous injection of insulin 
Detemir. The Jhee et al cohort had the most prolonged action and this longer action could be because 
they received the subcutaneous injection in the thigh, where, in contrast, the Brunner et al, and 
Heinemann et al cohorts both received a para-umbilical skin fold injection. The Heinemann cohort also 
received an intravenous infusion of human insulin throughout the study. These differences may account 
for differences in parameter values where greater consistency might otherwise be expected. 
 
A different potential source of this error is body weight, where weight varied between and within study 
cohorts. A constant volume of distribution for insulin in plasma of 4.0L was used in this analysis, based 
on previous work and non-reporting of weight in one study. However, as weights vary, it could explain 
some of the dose-dependent variability across studies, as seen for example between the Japanese and 
Caucasian cohorts in the Jhee et al study (Table 2). Thus, a similar sized U/kg dose can appear very 
differently in different subjects and studies. This error could shift curves by +/-10-20% at most, or equally 
this value improves the qualitative comparisons in Figures 3-4.  Therefore, further studies to validate 
the model need to include weight and/or BMI explicitly so subject specific volumes of distribution can 
be employed [38,39]. 
 
However, it is important to note the kinetics of insulin appearance, which is the main goal of this model 
are not a function of cohort. Disappearance from plasma due to action at the receptor is where cohort 
differences arise. Thus, the three parameters identified are all related to the specific kinetics of the drug 
in the depot and plasma, and, critically, not its action. There are no reported reasons in our knowledge 
to indicate the existence of different diffusion/transport kinetics for insulin between the interstitial fluid 
and plasma for these populations. Hence, it is unlikely there are significant differences between T1D 
and T2D cohort parameters, although it remains to be demonstrated on larger trials with specific cohorts 
which the results here could justify. 
 
Further, all five studies measured the serum insulin Detemir by an enzyme-linked immunosorbent assay 
(ELISA) developed by NovoNordisk using monoclonal antibodies recognizing the acylation site of 
insulin Detemir. Thus, dosing area and method may cause this variability, while measurement method 
was consistent. Since there was also no weights provided for the subjects in the Heinemann and 
Brunner cohorts these values had to be estimated which contributes to the variability as it modifies the 
distribution volumes in the modeling of any pharmacokinetics and is particularly sensitive in insulin 
kinetics studies using this overall model framework [40-44]. In addition, assay methods should be 
carefully noted and kept consistent to minimise variability. Equally, the test method should be consistent 
across cohorts.   
 
Finally, The 7 compartment, 8 parameter model complexity can be considered a drawback, particularly 
with regard to identifiability of parameters to ensure an accurate, robust model [33,45,46]. Analysis of 
the current and several prior (not shown) model structures indicated simpler models were not able to 
capture the pharmacokinetic profiles accurately with lesser compartments or parameters. The cause is 
the bound/free action of Detemir with albumin, which is what makes it unique. As a result, this action 
also requires including both these compartments to accurately capture its appearance profile.  
 
More specifically, the rate parameters for this binding are easily estimated from published ratios of free 
and bound Detemir. The latter clearance and diffusion between whole body plasma and interstitium is 
based on an existing, well-validated model of insulin kinetics. Thus, the key compartments for potential 
simplification are the local depot compartments, where they proved necessary to capture the peak and 
decay rate of the published appearance profiles. Hence, the model presented is actually the simpler of 
some others examined that is able to capture this unique action and its resulting impact on appearance 
kinetics. 
 
As a result of the limitations noted, the model developed in this study should be validated against clinical 
data from an independent cohort, particularly one focusing on T2D for this application. Better, more 
extensive controlled experiments across the cohorts in the studies used here, particularly target cohorts 
with T1D and T2D, would enable better determination of the robustness of the model, where the 
variability limits the ability of this analysis to provide more than a proof of concept validation. However, 





The model developed in this study provides acceptable model fits, is robust across cohorts to within 
measurement error, although limited by variations in study methods and assays. All observed dynamics 
appear to be captured, although some dose specific dynamics may exist, and potentially cohort specific 
dynamics for individuals with type 1 diabetes. The overall modeling approach may also be generalisable 
to other drugs utilising a similar albumin binding mechanism for transport and delayed action. The 
overall results show the model is a physiologically accurate representation of insulin Detemir 
pharmacokinetics in the human body, and can thus be used in model-based analyses of glycemia and 
glycemic control, although further extended tests with greater consistency in methods and assays are 





Funding: this research was partly funded by the New Zealand National Science Challenge Science for 
Technological Innovation (SfTI), sourced from the NZ Tertiary Education Commission (TEC), grant 
number CRS-S3-2016.  
 
Ethics Approval: The data used in this study was sourced from published literature and no new clinical 
data was used. There is thus no need for ethics approval. 
 






1. Shaw, J.E., R.A. Sicree, and P.Z. Zimmet, Global estimates of the prevalence of diabetes for 
2010 and 2030. Diabetes Res Clin Pract, 2010. 87(1): p. 4-14. 
2. Whiting, D.R., L. Guariguata, C. Weil, and J. Shaw, IDF diabetes atlas: global estimates of the 
prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract, 2011. 94(3): p. 311-21. 
3. Wild, S., G. Roglic, A. Green, R. Sicree, and H. King, Global prevalence of diabetes: estimates 
for the year 2000 and projections for 2030. Diabetes Care, 2004. 27(5): p. 1047-53. 
4. Zhang, P., X. Zhang, J. Brown, D. Vistisen, R. Sicree, J. Shaw, and G. Nichols, Global healthcare 
expenditure on diabetes for 2010 and 2030. Diabetes Res Clin Pract, 2010. 87(3): p. 293-301. 
5. Chatterjee, S., K. Khunti, and M.J. Davies Type 2 Diabetes. The Lancelet, 2017. 389(10085): p. 
12. 
6. Wallace, J.P., J.L. Wallace, and M.S. McFarland, Comparing dosing of basal insulin analogues 
detemir and glargine: is it really unit-per-unit and dose-per-dose? Ann Pharmacother, 2014. 
48(3): p. 361-8. 
7. Batais, M.A. and P. Schantter, Prevalence of unwillingness to use insulin therapy and its 
associated attitudes amongst patients with Type 2 diabetes in Saudi Arabia. Prim Care 
Diabetes, 2016. 10(6): p. 415-424. 
8. Philis-Tsimikas, A., Initiating basal insulin therapy in type 2 diabetes: practical steps to optimize 
glycemic control. Am J Med, 2013. 126(9 Suppl 1): p. S21-7. 
9. Edelman, S. and J. Pettus, Challenges associated with insulin therapy in type 2 diabetes 
mellitus. Am J Med, 2014. 127(10 Suppl): p. S11-6. 
10. Havelund, S., A. Plum, U. Ribel, I. Jonassen, A. Volund, J. Markussen, and P. Kurtzhals, The 
mechanism of protraction of insulin detemir, a long-acting, acylated analog of human insulin. 
Pharm Res, 2004. 21(8): p. 1498-504. 
11. Banks, W.A., J.E. Morley, J.L. Lynch, K.M. Lynch, and A.D. Mooradian, Insulin detemir is not 
transported across the blood-brain barrier. Peptides, 2010. 31(12): p. 2284-8. 
12. Dea, M.K., M. Hamilton-Wessler, M. Ader, D. Moore, L. Schaffer, M. Loftager, A. Volund, and 
R.N. Bergman, Albumin binding of acylated insulin (NN304) does not deter action to stimulate 
glucose uptake. Diabetes, 2002. 51(3): p. 762-9. 
13. Thabit, H., S. Hartnell, J.M. Allen, A. Lake, M.E. Wilinska, Y. Ruan, M.L. Evans, A.P. Coll, and R. 
Hovorka, Closed-loop insulin delivery in inpatients with type 2 diabetes: a randomised, parallel-
group trial. Lancet Diabetes Endocrinol, 2017. 5(2): p. 117-124. 
14. Rowley, W.R., C. Bezold, Y. Arikan, E. Byrne, and S. Krohe, Diabetes 2030: Insights from 
Yesterday, Today, and Future Trends. Popul Health Manag, 2017. 20(1): p. 6-12. 
15. Bally, L., H. Thabit, S. Hartnell, E. Andereggen, Y. Ruan, M.E. Wilinska, M.L. Evans, M.M. Wertli, 
A.P. Coll, C. Stettler, and R. Hovorka, Closed-Loop Insulin Delivery for Glycemic Control in 
Noncritical Care. N Engl J Med, 2018. 379(6): p. 547-556. 
16. Wong, J., J.G. Chase, C.E. Hann, T.F. Lotz, J. Lin, A. Le Compte, and G.M. Shaw, In Silico 
Simulation of Long-Term Type 1 Diabetes Glycemic Control Treatment Outcomes. Journal of 
Diabetes Science and Technology, 2008. 2(3): p. 425-435. 
17. Wong, J., J.G. Chase, C.E. Hann, G.M. Shaw, T.F. Lotz, J. Lin, and A.J. Le Compte, A 
Subcutaneous Insulin Pharmacokinetic Model for Computer Simulation in a Diabetes Decision 
Support Role: Model Structure and Parameter Identification. Journal of Diabetes Science and 
Technology, 2008. 2(4): p. 658-671. 
18. Wong, J., J.G. Chase, C.E. Hann, G.M. Shaw, T.F. Lotz, J. Lin, and A.J. Le Compte, A 
Subcutaneous Insulin Pharmacokinetic Model for Computer Simulation in a Diabetes Decision 
Support Role: Validation and Simulation. Journal of Diabetes Science and Technology, 2008. 
2(4): p. 672-680. 
19. Tarin, C., E. Teufel, J. Pico, J. Bondia, and H.J. Pfleiderer, Comprehensive pharmacokinetic 
model of insulin Glargine and other insulin formulations. IEEE transactions on bio-medical 
engineering, 2005. 52(12): p. 1994-2005. 
20. Brunner, G.A., G. Sendhofer, A. Wutte, M. Ellmerer, B. Sogaard, A. Siebenhofer, S. 
Hirschberger, G.J. Krejs, and T.R. Pieber, Pharmacokinetic and pharmacodynamic properties 
of long-acting insulin analogue NN304 in comparison to NPH insulin in humans. Exp Clin 
Endocrinol Diabetes, 2000. 108(2): p. 100-5. 
21. Danne, T., K. Lupke, K. Walte, W. Von Schuetz, and M.A. Gall, Insulin detemir is characterized 
by a consistent pharmacokinetic profile across age-groups in children, adolescents, and adults 
with type 1 diabetes. Diabetes Care, 2003. 26(11): p. 3087-92. 
22. Jhee, S.S., W.H. Lyness, P.B. Rojas, M.T. Leibowitz, V. Zarotsky, and L.V. Jacobsen, Similarity of 
insulin detemir pharmacokinetics, safety, and tolerability profiles in healthy caucasian and 
Japanese american subjects. J Clin Pharmacol, 2004. 44(3): p. 258-64. 
23. Wong, J., Model-Based Therapeutics for Type 1 Diabetes Mellitus. 2008, University of 
Canterbury: Christchurch, New Zealand. p. 259. 
24. Lotz, T.F., J.G. Chase, K.A. McAuley, G.M. Shaw, X.W. Wong, J. Lin, A. Lecompte, C.E. Hann, and 
J.I. Mann, Monte Carlo analysis of a new model-based method for insulin sensitivity testing. 
Comput Methods Programs Biomed, 2008. 89(3): p. 215-25. 
25. Li, J. and Y. Kuang, Systemically modeling the dynamics of plasma insulin in subcutaneous 
injection of insulin analogues for type 1 diabetes. Math Biosci Eng, 2009. 6(1): p. 41-58. 
26. Kurtzhals, P., S. Havelund, I. Jonassen, B. Kiehr, U.D. Larsen, U. Ribel, and J. Markussen, 
Albumin binding of insulins acylated with fatty acids: characterization of the ligand-protein 
interaction and correlation between binding affinity and timing of the insulin effect in vivo. 
Biochem J, 1995. 312 ( Pt 3): p. 725-31. 
27. Kurtzhals, P., S. Havelund, I. Jonassen, and J. Markussen, Effect of fatty acids and selected 
drugs on the albumin binding of a long-acting, acylated insulin analogue. J Pharm Sci, 1997. 
86(12): p. 1365-8. 
28. Soran, H. and N. Younis, Insulin detemir: a new basal insulin analogue. Diabetes Obes Metab, 
2006. 8(1): p. 26-30. 
29. Docherty, P.D., J.G. Chase, T.F. Lotz, and T. Desaive, A graphical method for practical and 
informative identifiability analyses of physiological models: a case study of insulin kinetics and 
sensitivity. Biomed Eng Online, 2011. 10: p. 39. 
30. Heinemann, L., K. Sinha, C. Weyer, M. Loftager, S. Hirschberger, and T. Heise, Time-action 
profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet Med, 
1999. 16(4): p. 332-8. 
31. Morrow, L., M. Hompesch, H. Guthrie, D. Chang, and D.J. Chatterjee, Co-administration of 
liraglutide with insulin detemir demonstrates additive pharmacodynamic effects with no 
pharmacokinetic interaction. Diabetes Obes Metab, 2011. 13(1): p. 75-80. 
32. Knopp, J.L., L. Holder-Pearson, and J.G. Chase, Insulin Units and Conversion Factors: A Story of 
Truth, Boots, and Faster Half-Truths. J Diabetes Sci Technol, 2018: p. 1932296818805074. 
33. Docherty, P.D., J.G. Chase, T.F. Lotz, and T. Desaive, A graphical method for practical and 
informative identifiability analyses of physiological models: A case study of insulin kinetics and 
sensitivity. Biomedical Engineering Online, 2011. 10(1): p. 1-20. 
34. Shimoda, S., K. Nishida, M. Sakakida, Y. Konno, K. Ichinose, M. Uehara, T. Nowak, and M. 
Shichiri, Closed-loop subcutaneous insulin infusion algorithm with a short-acting insulin analog 
for long-term clinical application of a wearable artificial endocrine pancreas. Front Med Biol 
Eng, 1997. 8(3): p. 197-211. 
35. Wong, J., J.G. Chase, C.E. Hann, G.M. Shaw, T.F. Lotz, J. Lin, and A.J. Compte, A subcutaneous 
insulin pharmacokinetic model for computer simulation in a diabetes decision support role: 
validation and simulation. J Diabetes Sci Technol, 2008. 2(4): p. 672-80. 
36. Priya, G. and S. Kalra, A Review of Insulin Resistance in Type 1 Diabetes: Is There a Place for 
Adjunctive Metformin? Diabetes Ther, 2018. 9(1): p. 349-361. 
37. Coresh, J., B.C. Astor, T. Greene, G. Eknoyan, and A.S. Levey, Prevalence of chronic kidney 
disease and decreased kidney function in the adult US population: Third National Health and 
Nutrition Examination Survey. Am J Kidney Dis, 2003. 41(1): p. 1-12. 
38. Turnheim, K. and W.K. Waldhausl, Essentials of insulin pharmacokinetics. Wien Klin 
Wochenschr, 1988. 100(3): p. 65-72. 
39. Despopoulos, A. and S. Silbernagl, Color atlas of physiology. 5th ed. Thieme flexibook. 2003, 
Stuttgart New York: G. Thieme 
Thieme Medical Publishers. x, 448 s. 
40. Docherty, P.D., J.G. Chase, T. Lotz, C.E. Hann, G.M. Shaw, J.E. Berkeley, J. Mann, and K. 
McAuley, DISTq: an iterative analysis of glucose data for low-cost, real-time and accurate 
estimation of insulin sensitivity. The Open Medical Informatics Journal, 2009. 3: p. 65. 
41. Docherty, P.D., J.G. Chase, T.F. Lotz, C.E. Hann, G.M. Shaw, J.E. Berkeley, L. TeMorenga, J.I. 
Mann, and K. McAuley, Independent cohort cross-validation of the real-time DISTq estimation 
of insulin sensitivity. Computer Methods and Programs in Biomedicine, 2011. 102(2): p. 94-
104. 
42. Docherty, P.D., J.G. Chase, L. Morenga, T.F. Lotz, J. Berkeley, G. Shaw, K. McAuley, and J. Mann, 
A spectrum of dynamic insulin sensitivity test protocols. Journal of Diabetes Science and 
Technology, 2011. 5(6): p. 1499. 
43. Lotz, T., High Resolution Clinical Model-Based Assessment of Insulin Sensitivity, in Mechanical 
Engineering. 2007, University of Canterbury: Christchurch. p. 231. 
44. Lotz, T.F., J.G. Chase, K.A. McAuley, G.M. Shaw, P.D. Docherty, J.E. Berkeley, S.M. Williams, 
C.E. Hann, and J.I. Mann, Design and clinical pilot testing of the model-based Dynamic Insulin 
Sensitivity and Secretion Test (DISST). Journal of Diabetes Science and Technology, 2010. 4(6): 
p. 1408-1423. 
45. Chase, J.G., J.C. Preiser, J.L. Dickson, A. Pironet, Y.S. Chiew, C.G. Pretty, G.M. Shaw, B. Benyo, 
K. Moeller, S. Safaei, M. Tawhai, P. Hunter, and T. Desaive, Next-generation, personalised, 
model-based critical care medicine: a state-of-the art review of in silico virtual patient models, 
methods, and cohorts, and how to validation them. Biomed Eng Online, 2018. 17(1): p. 24. 
46. Docherty, P.D., J.G. Chase, and T. David, Characterisation of the iterative integral parameter 
identification method. Medical and Biological Engineering and Computing, 2012: p. 1-8. 
 
